4-(6-氯吡嗪-2-基)吗啉 | 720693-19-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-(6-氯吡嗪-2-基)吗啉
• 中文别名: 4-(6-氯-2-吡嗪)吗啉
• 英文名称: 4-(6-chloropyrazin-2-yl)morpholine
• CAS: 720693-19-6
• 化学式: C₈H₁₀ClN₃O
• mdl: MFCD09800998
• 分子量: 199.64
• InChiKey: AVZHUCQUCHGNJF-UHFFFAOYSA-N

物化性质

• 沸点：
  351.6±42.0 °C(Predicted)
• 密度：
  1.320±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2934999090
• 储存条件：
  2-8℃

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(6-Chloropyrazin-2-yl)morpholine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(6-Chloropyrazin-2-yl)morpholine
CAS number: 720693-19-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H10ClN3O
Molecular weight: 199.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(6-氯吡嗪-2-基)吗啉 在 bis-triphenylphosphine-palladium(II) chloride 、 dichloro[1,1'-bis(di-t-butylphosphino)ferrocene]palladium(II) 、 三乙胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 2-benzyl-6-(6-morpholinopyrazin-2-yl)pyrrolo[1,2-a]pyrazin-1(2H)-one
  参考文献：
  名称：

  新型吡嗪取代的 1H-吡咯-2-甲酰胺和相关束缚杂环的合成

  摘要：

  作为药物发现计划的一部分，4-pyrrazin-2-yl-1 H -pyrrole-2-carboxamides 与许多双环类似物一起被使用。科学文献中基本上没有找到这些化合物的途径。4-(pyrazin-2-yl)-1 H -pyrrole-2-carboxamide 和几种稠合双环类似物的合成均使用标准程序（S N Ar、硼化、C-C 交叉偶联、水解、酰胺键形成、环化，卤化和烷基化）从容易获得的起始材料报道。每个最终化合物的合成序列范围为 4-12 步，分离中间体的产率范围为 20% 至 ∼100%。

  DOI：

  10.1055/s-0040-1719873
• 作为产物：
  描述：

  吗啉 、 2,6-二氯吡嗪 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 4.0h， 以88%的产率得到4-(6-氯吡嗪-2-基)吗啉
  参考文献：
  名称：

  新型吡嗪取代的 1H-吡咯-2-甲酰胺和相关束缚杂环的合成

  摘要：

  作为药物发现计划的一部分，4-pyrrazin-2-yl-1 H -pyrrole-2-carboxamides 与许多双环类似物一起被使用。科学文献中基本上没有找到这些化合物的途径。4-(pyrazin-2-yl)-1 H -pyrrole-2-carboxamide 和几种稠合双环类似物的合成均使用标准程序（S N Ar、硼化、C-C 交叉偶联、水解、酰胺键形成、环化，卤化和烷基化）从容易获得的起始材料报道。每个最终化合物的合成序列范围为 4-12 步，分离中间体的产率范围为 20% 至 ∼100%。

  DOI：

  10.1055/s-0040-1719873

文献信息

• [EN] CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS<br/>[FR] CYANOGUANIDINES ET LEUR UTILISATION COMME AGENTS ANTIVIRAUX
  申请人：ABBVIE INC

  公开号：WO2014005129A1

  公开（公告）日：2014-01-03

  This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

  这份披露涉及：(a) 抑制RSV感染和/或复制的化合物及其盐，等等；(b) 用于制备这些化合物和盐的中间体；(c) 包含这些化合物和盐的组合物；(d) 制备这些中间体、化合物、盐和组合物的方法；(e) 使用这些化合物、盐和组合物的方法；以及(f) 包含这些化合物、盐和组合物的试剂盒。
• [EN] BENZO ' D!AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS<br/>[FR] DERIVES BENZAZEPINE POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2004056369A1

  公开（公告）日：2004-07-08

  The present invention relates to benzazepine derivatives of formula ( I ) wherein: R1 represents -C3-7 cycloalkyl optionally substituted by C1-3 alkyl; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及公式（I）的苯并哌啶衍生物，其中：R1代表-C3-7环烷基，可选择地被C1-3烷基取代；具有药理活性，其制备方法，含有它们的组合物以及它们在治疗神经和精神疾病中的用途。
• 2-Thioxothiazolidin-4-one Analogs as Pan-PIM Kinase Inhibitors
  作者：Yanghwan Yun、Victor Sukbong Hong、Seungik Jeong、Hyeonseong Choo、Shin Kim、Jinho Lee

  DOI：10.1248/cpb.c21-00264

  日期：2021.9.1

  derivatives were synthesized and evaluated as potent pan-PIM kinase inhibitors. Optimized compounds showed single-digit nanomolar IC50 values against all three PIM kinases with high selectivity over 14 other kinases. Compound 17 inhibited the growth of Molm-16 cell lines (EC50 = 14 nM) and modulated the expression of pBAD and p4EBP1 in a dose-dependent manner. Fullsize Image

  莫洛尼鼠白血病病毒 (PIM) 激酶的原病毒整合位点是参与调节多种细胞过程的原癌激酶。PIM 激酶是新药开发的有希望的靶点，因为它们在许多癌症特异性途径中发挥重要作用，例如存活、细胞凋亡、增殖、细胞周期调节和迁移。在这里，2-thioxothiazolidin-4-one 衍生物被合成并评估为有效的泛 PIM 激酶抑制剂。优化的化合物对所有三种 PIM 激酶均显示出个位数纳摩尔 IC 50值，并且选择性高于其他 14 种激酶。化合物17抑制 Molm-16 细胞系 (EC 50  = 14 nM) 的生长并以剂量依赖性方式调节 pBAD 和 p4EBP1 的表达。 全尺寸图像
• Mild and General Conditions for Negishi Cross-Coupling Enabled by the Use of Palladacycle Precatalysts
  作者：Yang Yang、Nathan J. Oldenhuis、Stephen L. Buchwald

  DOI：10.1002/anie.201207750

  日期：2013.1.7

  A wide range of biaryls were synthesized by palladium‐catalyzed Negishi cross‐couplings at ambient temperature or with low catalyst loading. This protocol features the use of a recently reported aminobiphenyl palladacycle precatalyst to generate the catalytically active XPhosPd0 species. Significantly, a wide range of challenging heterocyclic and polyfluorinated aromatic substrates can be employed

  在环境温度或低催化剂负载量下，通过钯催化的根岸交叉偶联合成了多种联芳基化合物。该协议的特点是使用最近报道的氨基联苯钯环预催化剂来生成具有催化活性的 XPhosPd 0物质。值得注意的是，可以采用各种具有挑战性的杂环和多氟化芳香族底物来获得高产率的产品。
• [EN] 1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DERIVES D'ISOQUINILONE 1,4-DISUBSTITUES EN TANT QU'INHIBITEURS DE RAF-KINASE UTILES POUR LE TRAITEMENT DE MALADIES PROLIFERANTES
  申请人：NOVARTIS AG

  公开号：WO2005028444A1

  公开（公告）日：2005-03-31

  This invention relates to compounds of formula (I) wherein the variable substituents are described herein. The compounds are useful for the treatment of conditions and diseases characterized by an aberrant MAP kinase signaling pathway, such as cancer.

  本发明涉及式（I）化合物，其中变量取代基在本文中描述。这些化合物可用于治疗由异常的MAP激酶信号通路引起的疾病和症状，如癌症。